{"id":121,"date":"2006-11-12T14:37:25","date_gmt":"2006-11-12T21:37:25","guid":{"rendered":"https:\/\/stockherd.com\/moosepond\/?p=121"},"modified":"2006-11-12T14:37:25","modified_gmt":"2006-11-12T21:37:25","slug":"getting-ready-for-winter","status":"publish","type":"post","link":"https:\/\/stockherd.com\/moosepond\/2006\/11\/12\/getting-ready-for-winter\/","title":{"rendered":"Getting Ready for Winter"},"content":{"rendered":"<p>Most of our companies have announced their 3rd quarter results.&nbsp;  Here is an updated <a href=\"https:\/\/stockherd.com\/moosepond\/files\/rpts\/pert_20061110.pdf\">PERT chart<\/a> (portfolio evaluation review technique).&nbsp; Also, here is the portfolio <a href=\"https:\/\/stockherd.com\/moosepond\/files\/snapshot.htm\">summary<\/a>.&nbsp; The average quality rating for the portfolio is 67.5 (65 is very good) and average projected average return is 13.3%.&nbsp; <\/p>\n<p>In looking across the portfolio, two, possibly three, companies seem like good candidates for replacement.&nbsp;  These are Marsh &amp; McClennan (MMC) and Affiliated Computer Systems (ACS).&nbsp;  The third possibility is Pfizer (PFE).&nbsp;   We may want to consider replacing these companies with smaller quality companies with better growth prospects.&nbsp; Also, we should look at adding to our position in some of our better holdings.<\/p>\n<p><b>Marsh &amp; McClennan<\/b> has not yet recovered from its myriad of regulatory problems.  Click <a href=\"https:\/\/stockherd.com\/moosepond\/files\/ssg\/mmc_20061110.pdf\">here<\/a> for a SSG.&nbsp;  It has failed to re-establish growth in either revenues or earnings.  Return on equity and pretax margins have dipped significantly, with no immediate sign of recovery.&nbsp;  It may be a good value stock  (Morningstar rates it 4-stars) but it currently fails as a quality growth stock.&nbsp;  MMC is a prime candidate for replacement.<\/p>\n<div align=\"center\"> <img decoding=\"async\" src=\"https:\/\/stockherd.com\/moosepond\/files\/img\/mmc_20061110.png\" \/><\/div>\n<p><b>Affiliated Computer Systems<\/b> seems unable to move forward.&nbsp;  Click <a href=\"https:\/\/stockherd.com\/moosepond\/files\/ssg\/acs_20061110.pdf\">here<\/a> for a SSG.&nbsp;  As the chart below shows, it seem it has been unable to grow its revenue and earnings in any significant way over the past 4-5 quarters.&nbsp; It is now mired in an options pricing mess and will have to restate its earnings.&nbsp;  ACS failed to fully report its current quarter and instead offered up instead &#8220;non-GAAP&#8221; (GAAP = generally accepted accounting principles) metrics of performance.&nbsp;  Its TTM pre-tax margin (10.5%) is below the industry average (15.8%).&nbsp;  Morningstar still rates ACS 4-stars but also rates it F for stewardship.&nbsp;  ACS may be a decent company about to turn the corner &#8212; assuming its options pricing problem doesn&#8217;t get worse &#8212; but it seems to be another prime candidate for replacement. <\/p>\n<div align=\"center\"><img decoding=\"async\" src=\"https:\/\/stockherd.com\/moosepond\/files\/img\/acs_20061110.png\" style=\"margin: 0px;\" border=\"0\" \/><\/div>\n<p><b>Pfizer<\/b> is no longer a classic growth stock.  It&#8217;s price has rebounded in the last 12 months up more then 22%.&nbsp;  However, both growth and quality of earnings are in doubt gonig forward.&nbsp; Sales projections over the next 5 years vary from 2.6% to 6%.  Click <a href=\"https:\/\/stockherd.com\/moosepond\/files\/ssg\/pfe_20061110.pdf\">here<\/a> for a SSG.&nbsp;  PFE might be a good candidate for replacement.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Most of our companies have announced their 3rd quarter results.&nbsp; Here is an updated PERT chart (portfolio evaluation review technique).&nbsp; Also, here is the portfolio summary.&nbsp; The average quality rating for the portfolio is 67.5 (65 is very good) and average projected average return is 13.3%.&nbsp; In looking across the portfolio, two, possibly three, companies [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_jetpack_memberships_contains_paid_content":false,"_links_to":"","_links_to_target":""},"categories":[3],"tags":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/posts\/121"}],"collection":[{"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/comments?post=121"}],"version-history":[{"count":0,"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/posts\/121\/revisions"}],"wp:attachment":[{"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/media?parent=121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/categories?post=121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockherd.com\/moosepond\/wp-json\/wp\/v2\/tags?post=121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}